By contrast erlotinib, an EGFR tyrosine kinase inhibitor widely used for the treatment of NSCLC patients, significantly modulates in vitro the phenotype of lung cancer cell lines toward a more epithelial ones and promotes tumor sensitivity to NK-mediated lysis by restoring susceptibility to caspase-dependent pathways [187]. The gene discussed is EGFR; the disease is neoplasm.